Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10738651 | 0.94 | ELANE (0.55) | ELANEMEN1KMT2APTGS1CA1 | |
| SCHEMBL11476865 | 0.94 | ELANE (0.55) | ELANEMEN1KMT2APTGS1CA1 | |
| SCHEMBL10733750 | 0.92 | ELANE (0.55) | ELANEMEN1KMT2APTGS1CA1 | |
| SCHEMBL30860741 | 0.92 | ELANE (0.55) | ELANEMEN1KMT2APTGS1CA1 | |
| SCHEMBL10733755 | 0.92 | ELANE (0.55) | ELANEMEN1KMT2APTGS1CA1 | |
| SCHEMBL10736041 | 0.92 | ELANE (0.67) | ELANEMEN1KMT2APTGS1KDM4E | |
| SCHEMBL10371074 | 0.92 | ELANE (0.67) | ELANEMEN1KMT2APTGS1KDM4E | |
| SCHEMBL10735801 | 0.92 | ELANE (0.67) | ELANEMEN1KMT2APTGS1KDM4E | |
| SCHEMBL10735805 | 0.92 | ELANE (0.67) | ELANEMEN1KMT2APTGS1KDM4E | |
| SCHEMBL10592858 | 0.88 | ELANE (0.52) | ELANEMEN1KMT2APTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084833-B2 | Antibacterial agents against D,D- and L,D-transpeptidases | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200040005-A1 | ANTIBACTERIAL AGENTS AGAINST D,D- AND L,D-TRANSPEPTIDASES | THE JOHNS HOPKINS UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084833-B2 | Antibacterial agents against D,D- and L,D-transpeptidases | PEPD, DNPEP, NAALAD2 | ELANE 80/4885MEN1 4203/4885KMT2A 4213/4885 |
| US-20200040005-A1 | ANTIBACTERIAL AGENTS AGAINST D,D- AND L,D-TRANSPEPTIDASES | PEPD, DNPEP, NAALAD2 | ELANE 80/4885MEN1 4203/4885KMT2A 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.